Prognostic impact of cN-III mRNA expression on overall survival and drug sensitivity in pediatric leukemia

Leuk Lymphoma. 2022 Feb;63(2):457-462. doi: 10.1080/10428194.2021.1992616. Epub 2021 Oct 18.

Authors

Carine Domenech^{1

2

3}, Adriana Plesa^{2

3}, Anne Tourette², Yves Bertrand^{1

3

4}, Arthur Dony¹, Charles Dumontet^{2

3}, Emeline Cros-Perrial², Lars P Jordheim²

Affiliations

¹ Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France.
² Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.
³ Hospices Civils de Lyon, Lyon, France.
⁴ Univ Lyon, Université Claude Bernard, Lyon 1, France.

PMID: 34661502
DOI: 10.1080/10428194.2021.1992616

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Child
Disease-Free Survival
Gene Expression Regulation, Leukemic*
Humans
Leukemia, Myeloid, Acute* / genetics
Prognosis
RNA, Messenger / genetics

Substances

RNA, Messenger